Approval · Notice of Compliance 26394 · 2021
ATRIANCE: Notice of Compliance 26394
Issued August 9, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 26394
- Date
- August 9, 2021
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Change the storage conditions of the finished product. Migrate the Product Monograph to the 2020 format.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ATRIANCE | Not yet assigned | — |
Medicinal ingredients
- NELARABINE 5 MG per ML